First IGF-1R antibody for thyroid eye disease in China

14 March 2025

Innovent Biologics (HKEX: 01801) has gained approval in China for Sycume (teprotumumab), the country’s first IGF-1R antibody for thyroid eye disease (TED).

The National Medical Products Administration (NMPA) cleared the treatment, making it the second IGF-1R antibody therapy approved globally.

The company noted that Sycume's approval marks the first new TED therapy in China in 70 years. Lei Qian, senior vice president of clinical development, highlighted the significance of the milestone, stating that the drug’s approval: “not only highlights Innovent’s innovative R&D capabilities” but also reflects recognition from regulators of its clinical value.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK